{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Childhood+Malignant+Glioma&page=2", "query": { "condition": "Childhood Malignant Glioma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Childhood+Malignant+Glioma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-26T01:12:46.138Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00101270", "title": "Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Burkitt Lymphoma", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Diffuse Large Cell Lymphoma", "Childhood Grade III Lymphomatoid Granulomatosis", "Childhood Immunoblastic Large Cell Lymphoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Liver Cancer", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Malignant Germ Cell Tumor", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway Glioma", "Recurrent Colon Cancer", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Melanoma", "Recurrent Nasopharyngeal Cancer", "Recurrent Neuroblastoma", "Recurrent Osteosarcoma", "Recurrent Wilms Tumor and Other Childhood Kidney Tumors", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 24, "start_date": "2005-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-05", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 1, "location_summary": "Arcadia, California", "locations": [ { "city": "Arcadia", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00101270" }, { "nct_id": "NCT00983398", "title": "Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Nervous System Embryonal Neoplasm", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Germ Cell Tumor", "Medulloblastoma", "Medulloepithelioma", "Primitive Neuroectodermal Tumor", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Germ Cell Tumor", "Recurrent Medulloblastoma", "Recurrent Primitive Neuroectodermal Tumor" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Mannitol", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sodium Thiosulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 17, "start_date": "2009-07-09", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2021-10-26", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 2, "location_summary": "Minneapolis, Minnesota • Portland, Oregon", "locations": [ { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00983398" }, { "nct_id": "NCT00095940", "title": "Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Oligodendroglioma" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 52, "start_date": "2004-10", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2014-05-23", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00095940" }, { "nct_id": "NCT03860376", "title": "Ex Vivo Drug Sensitivity Testing and Mutation Profiling", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Large Cell Lymphoma", "Refractory Childhood Acute Lymphoblastic Leukemia", "Refractory Childhood Hodgkin Lymphoma", "Refractory Childhood Malignant Germ Cell Neoplasm", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Brainstem Glioma", "Recurrent Childhood Rhabdomyosarcoma", "Recurrent Childhood Soft Tissue Sarcoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Gliosarcoma", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive" ], "interventions": [], "intervention_types": [], "sponsor": "Florida International University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Day to 21 Years" }, "enrollment_count": 25, "start_date": "2019-02-21", "completion_date": "2022-12-31", "has_results": false, "last_update_posted_date": "2023-05-10", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860376" }, { "nct_id": "NCT00006246", "title": "Busulfan in Treating Children and Adolescents With Refractory CNS Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Childhood Germ Cell Tumor", "Leukemia", "Lymphoma", "Metastatic Cancer", "Retinoblastoma", "Sarcoma" ], "interventions": [ { "name": "busulfan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pediatric Brain Tumor Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 28, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2009-10-07", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 8, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006246" }, { "nct_id": "NCT00452868", "title": "Donepezil in Treating Young Patients With Primary Brain Tumors Previously Treated With Radiation Therapy to the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Cognitive/Functional Effects", "Long-term Effects Secondary to Cancer Therapy in Children", "Neurotoxicity", "Psychosocial Effects of Cancer and Its Treatment", "Radiation Toxicity" ], "interventions": [ { "name": "Donepezil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "8 Years to 17 Years" }, "enrollment_count": 14, "start_date": "2006-06", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 2, "location_summary": "Boston, Massachusetts • Winston-Salem, North Carolina", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452868" }, { "nct_id": "NCT00004212", "title": "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "exatecan mesylate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": null, "start_date": "1999-09", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 4, "location_summary": "New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004212" }, { "nct_id": "NCT00238173", "title": "Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bone Marrow Suppression", "Brain and Central Nervous System Tumors", "Drug/Agent Toxicity by Tissue/Organ", "Long-term Effects Secondary to Cancer Therapy in Children" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "acetylcysteine", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide phosphate", "type": "DRUG" }, { "name": "mannitol", "type": "DRUG" }, { "name": "sodium thiosulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "18 Years", "sex": "ALL", "summary": "1 Year to 18 Years" }, "enrollment_count": 2, "start_date": "2004-12", "completion_date": "2006-02-17", "has_results": false, "last_update_posted_date": "2017-04-21", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00238173" }, { "nct_id": "NCT00107471", "title": "Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Brain Tumors", "Central Nervous System Tumors" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "topotecan hydrochloride", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 7, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-10", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 72, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 62 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Downey", "state": "California" }, { "city": "Madera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107471" }, { "nct_id": "NCT02095132", "title": "Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Central Nervous System Embryonal Tumor With Rhabdoid Features", "Central Nervous System Embryonal Tumor, Not Otherwise Specified", "Central Nervous System Ganglioneuroblastoma", "Embryonal Tumor With Multilayered Rosettes, C19MC-Altered", "Pineoblastoma", "Primary Central Nervous System Neoplasm", "Recurrent Childhood Central Nervous System Embryonal Neoplasm", "Recurrent Malignant Solid Neoplasm", "Recurrent Medulloblastoma", "Recurrent Neuroblastoma", "Recurrent Rhabdomyosarcoma", "Refractory Malignant Solid Neoplasm", "Refractory Medulloblastoma", "Refractory Neuroblastoma", "Refractory Rhabdomyosarcoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 76, "start_date": "2014-03-28", "completion_date": "2023-06-30", "has_results": true, "last_update_posted_date": "2023-09-26", "last_synced_at": "2026-06-26T01:12:46.138Z", "location_count": 23, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02095132" } ] }